Skip to main content

Avance Clinical Joins Medrio’s ‘Trial Talks’ Podcast about Why Clinical Trials are Thriving in Australia

By July 30, 2020July 13th, 2021Company News, Partner News

The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical, joins Medrio’s new podcast series Trial Talks (listen here

Medrio, Inc. is the leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets. The first of the new Trial Talks podcast series features Avance Clinical CEO Yvonne Lungershausen and Director of Business Development Operations Sandrien Louwaars interviewed by Mike Novotny, CEO at Medrio.

Trial Talks is a clinical trials podcast series hosted by Medrio thought leaders. Trial Talks season one will focus on industry trends and challenges, unique solutions, and the perseverance of the industry through one of our toughest challenges, COVID-19.

Trial Talks season 1, episode 1 “Why Clinical Trials are Thriving in Australia” focuses on how Avance Clinical prepared for the pandemic, what tools were leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.

Medrio and Avance Clinical recently reached a milestone of supporting 150 clinical trials together.

Medrio and Avance Clinical’s successful partnership began in 2012 on a Phase I study with 103 patients and 14 sites, with Avance Clinical being Medrio’s first CRO partner in the Asia-Pacific.

Avance Clinical has utilized Medrio’s electronic data capture (EDC) solution successfully for the past eight years supporting 158 Phase I studies, 6,047 patients, and 236 sites. The HRECs usual review cycle in Australia, which takes only 4 to 8 weeks, coupled with Medrio’s ability to achieve FPI in less than three weeks is a perfect combination for accelerating study starts, a critical component to Phase I trials.

Yvonne Lungershausen, CEO at Avance Clinical said:

“Medrio has always been a wonderful partner to Avance Clinical. In addition to their EDC, we’ve used their ePRO and Direct Capture solutions, and we’re always impressed by not only their speed and flexibility but also their support. We know that if we have a question or need assistance that it will be addressed immediately and resolved quickly. Our partnership continues to flourish through ongoing clinical trials. We also recently had a great conversation with Medrio on their podcast, Trial Talks, about Australia’s unique position in the midst of COVID-19. I look forward to the continued success and growth of our partnership.”

Mike Novotny, CEO Medrio said:

“I’ve always been data-driven, and reaching the 150 trials milestone speaks volumes about Medrio and Avance’s relationship. Trust is earned, and I’d like to think that we’ve shown that we offer not only sophisticated clinical trial technology but also pride in our work. Our support team is available 24/7 and I am always proud to hear our customers speak so highly of them.

At Medrio we always have the patients in mind, and the faster we can get a trial up and running or provide support, the faster the patients in need will have the drugs, therapies, or devices that they need. I enjoyed interviewing Yvonne Lungershausen (CEO) and Sandrien Louwaars (Director of Business Development Operations) for the first Trial Talks podcast episode. It was fascinating to hear how Australia and New Zealand are operating in the midst of a global pandemic, and it highlights the perseverance of the industry and the Golden Age of pharma.”

About Medrio
Medrio is the leading provider of eClinical technology for pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and Contract Research Organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 600 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit

Leave a Reply